Medpace Holdings, Inc.
MEDP- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- SEC CIK
- 0001668397
In the last 90 days, Medpace Holdings, Inc. insiders filed 0 open-market purchases and 20 sales; 700 institutions reported holding it in 13F filings for Q2 2026, worth $13.1B in total; superinvestors Giverny Capital and Fundsmith hold it.
13F holders, Q3 2021
Institutional positions in Medpace Holdings, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 338
- +19 vs. Q2 2021
- Shares held
- 28.6M
- +1.04M (+3.8%) vs. Q2 2021
- Total value
- $5.42B
- +$536.7M (+11.0%) vs. Q2 2021
- New holders
- 39
- 139 more added
- Sold out
- 20
- 114 more reduced
5 institutions that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting MEDP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 700 | $13.1B |
| Q1 2026 | 734 | $11.6B |
| Q4 2025 | 788 | $13.4B |
| Q3 2025 | 673 | $12.3B |
| Q2 2025 | 602 | $8.28B |
| Q1 2025 | 585 | $7.77B |
| Q4 2024 | 592 | $8.42B |
| Q3 2024 | 584 | $8.47B |
| Q2 2024 | 623 | $10.4B |
| Q1 2024 | 595 | $10.2B |
| Q4 2023 | 544 | $7.55B |
| Q3 2023 | 490 | $5.81B |
| Q2 2023 | 464 | $5.78B |
| Q1 2023 | 417 | $4.68B |
| Q4 2022 | 423 | $5.17B |
| Q3 2022 | 357 | $4.06B |
| Q2 2022 | 341 | $3.94B |
| Q1 2022 | 349 | $4.48B |
| Q4 2021 | 386 | $6.24B |
| Q3 2021 | 338 | $5.42B |
| Q2 2021 | 324 | $4.88B |
| Q1 2021 | 319 | $4.59B |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Medpace Holdings, Inc.; share changes are against Q2 2021.